Revised international prognostic scoring system for myelodysplastic syndromes.

The International Prognostic Scoring System (IPSS) is an important standard for assessing prognosis of primary untreated adult patients with myelodysplastic syndromes (MDS). To refine the IPSS, MDS patient databases from international institutions were coalesced to assemble a much larger combined database (Revised-IPSS [IPSS-R], n = 7012, IPSS, n = 816) for analysis. Multiple statistically weighted clinical features were used to generate a prognostic categorization model. Bone marrow cytogenetics, marrow blast percentage, and cytopenias remained the basis of the new system. Novel components of the current analysis included: 5 rather than 3 cytogenetic prognostic subgroups with specific and new classifications of a number of less common cytogenetic subsets, splitting the low marrow blast percentage value, and depth of cytopenias. This model defined 5 rather than the 4 major prognostic categories that are present in the IPSS. Patient age, performance status, serum ferritin, and lactate dehydrogenase were significant additive features for survival but not for acute myeloid leukemia transformation. This system comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS. As such, this IPSS-R should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease.

[1]  C. Bloomfield,et al.  NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[3]  Jean McGowan-Jordan,et al.  ISCN 2013 : an international system for human cytogenetic nomenclature (2013) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature , 2005 .

[4]  V. V. D. van der Velden,et al.  Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. , 2008, Blood.

[5]  M. Cazzola,et al.  Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) , 2011, Haematologica.

[6]  C. Fonatsch,et al.  Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. , 2001, Leukemia research.

[7]  C. Gross,et al.  Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. , 2009, Leukemia research.

[8]  A. Verma,et al.  Cytokine targets in the treatment of myelodysplastic syndromes. , 2005, Current hematology reports.

[9]  Luca Malcovati,et al.  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome , 2011, Haematologica.

[10]  A. Órfão,et al.  Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group , 2012, Leukemia.

[11]  C. Steidl,et al.  Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) , 2005, Leukemia.

[12]  C. Declercq,et al.  Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniques , 1996, British journal of haematology.

[13]  L. Arenillas,et al.  Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome , 2008 .

[14]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.

[15]  C. Fonatsch,et al.  Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  A. Hagemeijer,et al.  Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Valent,et al.  Impact of age and comorbidity in myelodysplastic syndromes. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  C. Bloomfield,et al.  The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes , 2009 .

[19]  D. Costa,et al.  The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. , 2012, Leukemia research.

[20]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Cazzola,et al.  14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM) , 2011 .

[22]  A. Ganser,et al.  Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes , 2008, Leukemia.

[23]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[24]  C E Minder,et al.  A robust method for proportional hazards regression. , 1996, Statistics in medicine.

[25]  P. Valent,et al.  Comorbidity as Prognostic Variable in MDS: Comparative Evaluation of the HCT-CI and CCI in a Core Data Set of 582 Patients of the Austrian MDS Platform. , 2008 .

[26]  P. Greenberg,et al.  International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes , 2008, American journal of hematology.

[27]  H. Kantarjian,et al.  The incidence and impact of thrombocytopenia in myelodysplastic syndromes , 2007, Cancer.

[28]  P. Valent,et al.  Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[30]  J. Issa,et al.  Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System , 2008, Cancer.

[31]  M. Suarez‐Almazor,et al.  Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  References , 1971 .

[33]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Ken Chen,et al.  Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.

[35]  U. Germing,et al.  Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.

[36]  M. Pfeilstöcker,et al.  Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes. , 2012, Leukemia research.

[37]  Y. Rumpler,et al.  International Standing Committee on Human Cytogenetic Nomenclature , 1976 .

[38]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[39]  M. Ardanaz,et al.  Prognostic impact of severe thrombocytopenia in low‐risk myelodysplastic syndrome , 2011, Cancer.

[40]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T M Therneau,et al.  Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. , 1995, Biometrics.

[42]  H. Deeg,et al.  Negative Regulators of Hemopoiesis and Stroma Function in Patients with Myelodysplastic Syndrome , 2000, Leukemia & lymphoma.

[43]  U. Germing,et al.  Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. , 2009, Leukemia research.

[44]  A. Stamatoullas,et al.  Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. , 2011, Leukemia research.

[45]  E. Estey,et al.  Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). , 2003, Blood.

[46]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[47]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[48]  U. Germing,et al.  The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome , 2009, Haematologica.

[49]  M. Cazzola,et al.  Syndromes Revised International Prognostic Scoring System for Myelodysplastic , 2012 .

[50]  C. Bloomfield,et al.  Myelodysplastic SyndromesPractice Guidelines in Oncology , 2011 .

[51]  U. Germing,et al.  Myelodysplastic syndromes in patients younger than age 50. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[53]  M. Lübbert,et al.  Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  M. Cazzola,et al.  Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.